Gd-BOPTA在肝臟局灶性病變及膽道系統疾病診斷中的應用價值_《中國普外基礎與臨床雜志》

作者：

鐘歡歡 , 宋彬 , 陳光文

四川大學華西醫院放射科(成都 610041);

關鍵詞：

釓貝酸二葡甲胺肝臟局灶性病變膽道系統磁共振成像

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討磁共振雙功能對比劑釓貝酸二葡甲胺（Gd-BOPTA）在肝臟局灶性病變和膽道系統疾病診斷中的應用價值。方法在CNKI及PubMed上檢索近年來Gd-BOPTA在肝臟局灶性病變及膽道系統病變診斷中應用的文獻，對其應用價值進行綜述。結果在肝臟局灶性病變的診斷方面，Gd-BOPTA除了能反映病灶的血供情況外，還能反映病灶內肝細胞的功能狀態。在膽道系統評價方面，Gd-BOPTA可以用于評價膽囊運動功能、膽管解剖結構、變異及病變情況。結論 Gd-BOPTA對肝臟局灶性病變和膽道系統疾病的診斷有重要價值，具有廣闊的應用前景。

引用本文： 鐘歡歡,宋彬,陳光文. Gd-BOPTA在肝臟局灶性病變及膽道系統疾病診斷中的應用價值. 中國普外基礎與臨床雜志, 2009, 16(12): 1042-1046. doi: 復制

1.	Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP [Ｊ]. Magn Reson Med, 1996; 35(1): 14-19.
2.	Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase Ⅲ clinical study [Ｊ]. Radiology, 2000; 215(3): 727-736.
3.	Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions [Ｊ]. AJR Am J Roentgenol, 2000; 175(4): 1111-1120.
4.	Helmberger T, Semelka RC. New contrast agents for imaging the liver [Ｊ]. Magn Reson Imaging Clin N Am, 2001; 9(4): 745-766.
5.	Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine [Ｊ]. Radiology, 2001; 221(3): 731-739.
6.	del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations [Ｊ]. Radiology, 2002; 225(3): 766-772.
7.	Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview [Ｊ]. Invest Radiol, 1998; 33(11): 798-809.
8.	Giovagnoni A, Paci E. Liver. Ⅲ: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg) [Ｊ]. Magn Reson Imaging Clin N Am, 1996; 4(1): 61-72.
9.	Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging [Ｊ]. Invest Radiol, 1993; 28(8): 753-761.
10.	Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance [Ｊ]. Invest Radiol, 2006; 41(6): 500-509.
11.	Jeng CM, Tai SC, Wang YC, et al. Assessment of the adverse reactions of gadobenate dimeglumine (Gd-BOPTA) from preliminary clinical experience in taiwan [Ｊ]. Chin J Radiol, 2005; 30: 257-262.
12.	Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function [Ｊ]. Invest Radiol, 2002; 37(5): 299-308.
13.	Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned [Ｊ]. AJR Am J Roentgenol, 2007; 188(2): 586-592.
14.	Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency [Ｊ]. Am J Kidney Dis, 2000; 36(6): 1207-1212.
15.	Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors [Ｊ]. Invest Radiol, 2001; 36(11): 632-641.
16.	譚國強, 龍晚生, 周偉, 等. 肝局灶性結節增生的CT診斷及病理對照 [Ｊ]. 放射學實踐， 2008; 23（9）: 1018-1020.
17.	李迎春, 宋彬, 蔣莉莉, 等. 新型MR造影劑釓貝葡胺診斷肝臟局灶性結節樣增生的價值(附5例報告) [Ｊ]. 中國普外基礎與臨床雜志, 2007; 14（5）: 598-604.
18.	Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study [Ｊ]. Radiology, 2005; 236(1): 166-177.
19.	Hwang HS, Kim SH, Jeon TY, et al. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy [Ｊ]. Korean J Radiol, 2009; 10(3): 294-302.
20.	Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging [Ｊ]. Eur Radiol, 2005; 15(2): 220-228.
21.	Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma [Ｊ]. Adv Anat Pathol, 2007; 14(3): 217-223.
22.	盧延, 張雪哲主編. 腹部疾病影像鑒別診斷 [M]. 北京: 化學工業出版社， 2008： 100-101.
23.	Mitchell TS, Ellen RB, Paul J, et al. Fibrolamellar hepatocellular carcinoma [Ｊ]. Radio Graphics, 2008; 28（2）: 609-613.
24.	陳光文, 陳壢桃, 宋彬. 肝硬變相關結節的MR評價 [Ｊ]. 中國普外基礎與臨床雜志, 2009; 16（7）: 582-586.
25.	劉敏, 凌堅, 麥遠鋒, 等. 惡性肝腫瘤釓貝葡胺MR增強延遲掃描表現 [Ｊ]. 影像診斷與介入放射學, 2006; 15（2）: 67-69.
26.	張國福, 周榮康, 嚴福華, 等. Gd-BOPTA增強MRI對小肝癌的診斷價值 [Ｊ]. 臨床放射學雜志, 2004; 23（12）: 1052-1057.
27.	Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation [Ｊ]. Radiology, 1997; 205(3): 721-728.
28.	Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings [Ｊ]. Invest Radiol, 2000; 35(1): 25-34.
29.	Fayad LM, Holland GA, Bergin D, et al. Functional magnetic resonance cholangiography (fMRC) of the gallbladder and biliary tree with contrast-enhanced magnetic resonance cholangiography [Ｊ]. J Magn Reson Imaging, 2003; 18(4): 449-460.
30.	Fink-Bennett D. Hepatobiliary imaging [A]. In: Henkin RE Eds. Nuclear medicine [M]. 2nd ed. Philadelphia, PA: Mosby Elsevier, 2006: 968-987.
31.	Dahlstrm N, Persson A, Albiin N, et al. Contrast-enhan-ced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects [Ｊ]. Acta Radiol, 2007; 48(4): 362-368.
32.	Lim JS, Kim MJ, Myoung S, et al. MR cholangiography for evaluation of hilar branching anatomy in transplantation of the right hepatic lobe from a living donor [Ｊ]. AJR Am J Roentgenol, 2008; 191(2): 537-545.
33.	王宏, 穆學濤, 吳春楠, 等. 活體肝移植供體膽管造影-磁共振膽管水成像和莫迪司增強膽管造影對比 [Ｊ]. 生物醫學工程與臨床, 2008; 13（3）: 193-197.
34.	Akpinar E, Turkbey B, Karcaaltincaba M, et al. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis [Ｊ]. J Magn Reson Imaging, 2009; 30(3): 578-585.

1. Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP [Ｊ]. Magn Reson Med, 1996; 35(1): 14-19.
2. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase Ⅲ clinical study [Ｊ]. Radiology, 2000; 215(3): 727-736.
3. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions [Ｊ]. AJR Am J Roentgenol, 2000; 175(4): 1111-1120.
4. Helmberger T, Semelka RC. New contrast agents for imaging the liver [Ｊ]. Magn Reson Imaging Clin N Am, 2001; 9(4): 745-766.
5. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine [Ｊ]. Radiology, 2001; 221(3): 731-739.
6. del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations [Ｊ]. Radiology, 2002; 225(3): 766-772.
7. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview [Ｊ]. Invest Radiol, 1998; 33(11): 798-809.
8. Giovagnoni A, Paci E. Liver. Ⅲ: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg) [Ｊ]. Magn Reson Imaging Clin N Am, 1996; 4(1): 61-72.
9. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging [Ｊ]. Invest Radiol, 1993; 28(8): 753-761.
10. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance [Ｊ]. Invest Radiol, 2006; 41(6): 500-509.
11. Jeng CM, Tai SC, Wang YC, et al. Assessment of the adverse reactions of gadobenate dimeglumine (Gd-BOPTA) from preliminary clinical experience in taiwan [Ｊ]. Chin J Radiol, 2005; 30: 257-262.
12. Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function [Ｊ]. Invest Radiol, 2002; 37(5): 299-308.
13. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned [Ｊ]. AJR Am J Roentgenol, 2007; 188(2): 586-592.
14. Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency [Ｊ]. Am J Kidney Dis, 2000; 36(6): 1207-1212.
15. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors [Ｊ]. Invest Radiol, 2001; 36(11): 632-641.
16. 譚國強, 龍晚生, 周偉, 等. 肝局灶性結節增生的CT診斷及病理對照 [Ｊ]. 放射學實踐， 2008; 23（9）: 1018-1020.
17. 李迎春, 宋彬, 蔣莉莉, 等. 新型MR造影劑釓貝葡胺診斷肝臟局灶性結節樣增生的價值(附5例報告) [Ｊ]. 中國普外基礎與臨床雜志, 2007; 14（5）: 598-604.
18. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study [Ｊ]. Radiology, 2005; 236(1): 166-177.
19. Hwang HS, Kim SH, Jeon TY, et al. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy [Ｊ]. Korean J Radiol, 2009; 10(3): 294-302.
20. Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging [Ｊ]. Eur Radiol, 2005; 15(2): 220-228.
21. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma [Ｊ]. Adv Anat Pathol, 2007; 14(3): 217-223.
22. 盧延, 張雪哲主編. 腹部疾病影像鑒別診斷 [M]. 北京: 化學工業出版社， 2008： 100-101.
23. Mitchell TS, Ellen RB, Paul J, et al. Fibrolamellar hepatocellular carcinoma [Ｊ]. Radio Graphics, 2008; 28（2）: 609-613.
24. 陳光文, 陳壢桃, 宋彬. 肝硬變相關結節的MR評價 [Ｊ]. 中國普外基礎與臨床雜志, 2009; 16（7）: 582-586.
25. 劉敏, 凌堅, 麥遠鋒, 等. 惡性肝腫瘤釓貝葡胺MR增強延遲掃描表現 [Ｊ]. 影像診斷與介入放射學, 2006; 15（2）: 67-69.
26. 張國福, 周榮康, 嚴福華, 等. Gd-BOPTA增強MRI對小肝癌的診斷價值 [Ｊ]. 臨床放射學雜志, 2004; 23（12）: 1052-1057.
27. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation [Ｊ]. Radiology, 1997; 205(3): 721-728.
28. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings [Ｊ]. Invest Radiol, 2000; 35(1): 25-34.
29. Fayad LM, Holland GA, Bergin D, et al. Functional magnetic resonance cholangiography (fMRC) of the gallbladder and biliary tree with contrast-enhanced magnetic resonance cholangiography [Ｊ]. J Magn Reson Imaging, 2003; 18(4): 449-460.
30. Fink-Bennett D. Hepatobiliary imaging [A]. In: Henkin RE Eds. Nuclear medicine [M]. 2nd ed. Philadelphia, PA: Mosby Elsevier, 2006: 968-987.
31. Dahlstrm N, Persson A, Albiin N, et al. Contrast-enhan-ced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects [Ｊ]. Acta Radiol, 2007; 48(4): 362-368.
32. Lim JS, Kim MJ, Myoung S, et al. MR cholangiography for evaluation of hilar branching anatomy in transplantation of the right hepatic lobe from a living donor [Ｊ]. AJR Am J Roentgenol, 2008; 191(2): 537-545.
33. 王宏, 穆學濤, 吳春楠, 等. 活體肝移植供體膽管造影-磁共振膽管水成像和莫迪司增強膽管造影對比 [Ｊ]. 生物醫學工程與臨床, 2008; 13（3）: 193-197.
34. Akpinar E, Turkbey B, Karcaaltincaba M, et al. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis [Ｊ]. J Magn Reson Imaging, 2009; 30(3): 578-585.

《中國普外基礎與臨床雜志》

Gd-BOPTA在肝臟局灶性病變及膽道系統疾病診斷中的應用價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

Gd-BOPTA在肝臟局灶性病變及膽道系統疾病診斷中的應用價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料